Abstract

BackgroundParvalbumin, the major fish allergen, is responsible for IgE cross-reactivity among different fish species. We aimed to generate recombinant single chain antibody fragments (scFv) binding to epitopes responsible for IgE cross-reactivity among parvalbumins.MethodsThe parvalbumin-specific scFvs were selected from the human synthetic scFv phage library ETH-2 by alternating the parvalbumin from cod (Gad m 1), carp (Cyp c 1) and trout (Onc m 1) during 3 rounds of sequential biopanning. Based on their reactivity to parvalbumins by ELISA, 2 clones were expressed in Escherichia coli. The ability of the 2 scFv antibodies to inhibit the binding of parvalbumin-specific IgE from fish allergic patients’ sera was showed by ELISA competition experiments and the rat basophilic leukemia mediator release assay.ResultsBased on ability to bind different parvalbumins and sequence analysis, phage clones scFv-gco9 and scFv-goo8 were selected for production of soluble scFv antibodies. We obtained 1 mg of scFv-gco9 and 1.3 mg of scFv-goo8 per litre of bacterial culture. The scFv-gco9 was able to detect all 3 parvalbumins at a concentration of 10 ng/mL. The scFv-goo8 bound to cod parvalbumin, but not to carp and trout parvalbumin. The detection limit for 1 μg/mL of the scFv-gco9 was 0.01 μg/mL of the Gad m 1 and 0.2 μg/mL of Onc m 1 or Cyp c 1. We found that scFv-gco9 dose-dependently blocked the binding of IgE to immobilized Gad m 1, Cyp c 1 and Onc m 1. At a concentration of 5 μg/mL of scFv-gco9 binding of IgE to the 3 parvalbumins was inhibited by approximately 40%, and at a concentration of 20 μg/mL the IgE binding was inhibited to ∼70%. In the case of the scFv-goo8, inhibition of IgE binding to Gad m 1 was about 15%. The inhibition of degranulation of basophils was 55% in the presence of 2 μg/mL scFv-gco9.ConclusionsThis work, supported by grant SFB-F01802, revealed that the scFv antibodies can be used for the standardization of protein extracts used for allergy diagnosis and for IgE epitope mapping. Epitope characterization enables the engineering of parvalbumin molecules with reduced IgE binding for allergen-specific immunotherapy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.